Terms: = Colorectal cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
468 results:
1. Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.
Wang Z; Cheng S; Yao Y; Liu S; Liu Z; Liu N; Jin Y; Zhang Y; Yin F; Han G; Zhang J; Wang Q; Yan D; Wang L; Lu H; Deng T; Ji Z; Gao H; Fang W; Zhang H; Chen Z; Zou J; Tang Y; Xu C; Li J; Qu H; Bao L; Cao B; Wang X; Xu T; Sun Y; Shen L; Peng Z; Li J
Cancer Immunol Immunother; 2024 Jul; 73(9):182. PubMed ID: 38967817
[TBL] [Abstract] [Full Text] [Related]
2. DNA demethylase TET2-mediated reduction of HADHB expression contributes to cadmium-induced malignant progression of colorectal cancer.
Li L; Jiang M; Wang W; Cao X; Ma Q; Han J; Liu Z; Huang Y; Chen Y
Ecotoxicol Environ Saf; 2024 Jul; 280():116579. PubMed ID: 38865940
[TBL] [Abstract] [Full Text] [Related]
3. Short-term outcomes of surgical treatment for primary ileocaecal Crohn's disease: Results of the Crohn's(urg) study, a multicentre, retrospective, comparative analysis between inflammatory and complicated phenotypes.
Avellaneda N; Pellino G; Maroli A; Tottrup A; Bislenghi G; Colpaert J; D'Hoore A; Carvello M; Giorgi L; Juachon P; Harsløf S; de Buck Van Overstraeten A; Olivera PA; Gomez J; Holubar SD; Naranjo EL; Steele SR; Merchea A; Shaker A; Gallostra MM; Kraft M; Kotze PG; Maruyama BY; Wexner SD; Garoufalia Z; Chen Z; Hahnloser D; Rrupa D; Buskens C; Haanappel A; Warusavitarne J; Williams KJ; Christensen P; Wolthuis A; Potolicchio A; Spinelli A
Colorectal Dis; 2024 Jul; 26(7):1415-1427. PubMed ID: 38858815
[TBL] [Abstract] [Full Text] [Related]
4. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
[TBL] [Abstract] [Full Text] [Related]
5. ARHGAP4 promotes colon cancer metastasis through the TGF-β signaling pathway and may be associated with T cell exhaustion.
Jiang S; Tang Y; Wang X; Guo H; Chen L; Hu G; Cui Y; Liang S; Zuo J; Luo Z; Chen X; Wang X
Biochem Biophys Res Commun; 2024 Aug; 722():150172. PubMed ID: 38805788
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Biomarkers and Signaling Pathways of cancer Stem Cells in colorectal cancer.
Omran MM; Fouda MS; Mekkawy SA; Tabll AA; Abdelaziz AG; Omran AM; Emran TM
Technol Cancer Res Treat; 2024; 23():15330338241254061. PubMed ID: 38794896
[TBL] [Abstract] [Full Text] [Related]
7. Radiotherapy and immunology.
Wang L; Lynch C; Pitroda SP; Piffkó A; Yang K; Huser AK; Liang HL; Weichselbaum RR
J Exp Med; 2024 Jul; 221(7):. PubMed ID: 38771260
[TBL] [Abstract] [Full Text] [Related]
8. [Upregulating KLF11 ameliorates intestinal inflammation in mice with 2, 4, 6-trinitrobenesulfonic acid-induced colitis by inhibiting the JAK2/STAT3 signaling pathway].
Xi J; Zhang M; Zhang Y; Zhang C; Zhang Y; Wang R; Shen L; Li J; Song X
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Apr; 44(4):765-772. PubMed ID: 38708511
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn's and Colitis (IRCC).
Saberzadeh-Ardestani B; Khosravi AA; Mansour-Ghanaei F; Vahedi H; Baniasadi N; Seyyedmajidi M; Parhizkar B; Hormati A; Naghshbandi SJ; Matin S; Hassan Zadeh AA; Taghvaei T; Bahrami M; Rafeey M; Ahadi M; Vossoughinia H; Muosavi H; Gheibi S; Hosseini-Hemmatabadi RS; Yazdanbod A; Matinkhah S; Sheikh Esmaeili F; Fakheri H; Moosavy SH; Maleki I; Nasseri-Moghaddam S; Khosravi B; Farahmand F; Najafi M; Alimadadi H; Malekzadeh M; Anushiravani A; Kasaeian A; Alatab S; Sadeghi A; Radmard AR; Kolahdoozan S; Rajabi Z; Sima AR
Arch Iran Med; 2024 Apr; 27(4):183-190. PubMed ID: 38685844
[TBL] [Abstract] [Full Text] [Related]
10. Dissecting the Mechanisms of Intestinal Immune Homeostasis by Analyzing T-Cell Immune Response in Crohn's Disease and colorectal cancer.
Jiang T; Zheng J; Li N; Li X; He J; Zhou J; Sun B; Chi Q
Curr Gene Ther; 2024; 24(5):422-440. PubMed ID: 38682449
[TBL] [Abstract] [Full Text] [Related]
11. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/ctla4 using humanized mice.
Hou X; Liu S; Zeng Z; Wang Z; Ding J; Chen Y; Gao X; Wang J; Xiao G; Li B; Zhu H; Yang Z
Biomed Pharmacother; 2024 Jun; 175():116669. PubMed ID: 38677243
[TBL] [Abstract] [Full Text] [Related]
12. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
13. Association between Metabolic Reprogramming and Immune Regulation in Digestive Tract Tumors.
Liu J; Wang T; Zhang W; Huang Y; Wang X; Li Q
Oncol Res Treat; 2024; 47(6):273-286. PubMed ID: 38636467
[TBL] [Abstract] [Full Text] [Related]
14. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract] [Full Text] [Related]
15. Cimetidine repurposed as a potential immunomodulatory agent against colorectal carcinoma: A systematic review.
Gunasekara W; Sachindra J; Madhushika MT; Liyanage P; Lekamwasam S
J Oncol Pharm Pract; 2024 Jul; 30(5):930-936. PubMed ID: 38592456
[TBL] [Abstract] [Full Text] [Related]
16. [Expression of immune checkpoints PD-L1, ctla4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
17. Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.
Shen W; Li Y; Yang Z; Li W; Cao Y; Liu Y; Wang Z; Pei R; Xing C
J Nanobiotechnology; 2024 Apr; 22(1):154. PubMed ID: 38581017
[TBL] [Abstract] [Full Text] [Related]
18. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
He R; Huang S; Lu J; Su L; Gao X; Chi H
Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
[TBL] [Abstract] [Full Text] [Related]
19. Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.
Fróes RSB; Andrade AR; Faria MAG; de Souza HSP; Parra RS; Zaltman C; Dos Santos CHM; Bafutto M; Quaresma AB; Santana GO; Luporini RL; de Lima Junior SF; Miszputen SJ; de Souza MM; Herrerias GSP; Junior RLK; do Nascimento CR; Féres O; de Barros JR; Sassaki LY; Saad-Hossne R
Sci Rep; 2024 Feb; 14(1):4314. PubMed ID: 38383742
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High colorectal cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract] [Full Text] [Related]
[Next]
